Immunome Inc. announced positive topline results from its pivotal Phase 3 trial of varegacestat in desmoid tumors, with plans for NDA submission in Q2 2026. The company advances a diversified pipeline anchored by innovative ADC technology and novel payloads. Financials reflect ongoing strategic R&D investments with improving operating losses but significant cash burn. Upcoming clinical milestones and regulatory progress will be crucial as Immunome transitions toward potential commercialization.